

TRADEMARK ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Biosite Incorporated		06/29/2007	CORPORATION: DELAWARE

RECEIVING PARTY DATA

Name:	General Electric Capital Corporation, as Agent
Street Address:	2 Bethesda Metro Center, Suite 600
City:	Bethesda
State/Country:	MARYLAND
Postal Code:	20814
Entity Type:	CORPORATION: DELAWARE

PROPERTY NUMBERS Total: 15

Property Type	Number	Word Mark
Registration Number:	2453707	AN UNFAIR ADVANTAGE
Registration Number:	2476239	OMNICLONAL
Serial Number:	78574678	MULTI MARKER INDEX
Registration Number:	2601205	IN TIME TO DECIDE
Registration Number:	2757467	NEW DIMENSIONS IN DIAGNOSIS
Registration Number:	1923243	ASCEND MULTIMUNOASSAY
Registration Number:	1794618	BIOSITE
Registration Number:	1796567	BIOSITE
Registration Number:	3152581	BIOSITE
Registration Number:	1954150	TRIAGE
Registration Number:	2673476	TPP
Registration Number:	2207727	EXPRESS TEST
Registration Number:	2279640	EXPRESS TEST
Registration Number:	2960760	CARDIO PROFILER

OP \$390.00 2453707

900081108

TRADEMARK
REEL: 003575 FRAME: 0228

CORRESPONDENCE DATA

Fax Number: (212)230-7735

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 212-318-6535

Email: traceybennett@paulhastings.com

Correspondent Name: Tracey D. Bennett

Address Line 1: c/o Paul, Hastings

Address Line 2: 75 E. 55th Street

Address Line 4: New York, NEW YORK 10022

NAME OF SUBMITTER:	Tracey D. Bennett
Signature:	/s/Tracey D. Bennett
Date:	07/05/2007

Total Attachments: 47

source=First Lien IP Security Agt#page1.tif

source=First Lien IP Security Agt#page2.tif

source=First Lien IP Security Agt#page3.tif

source=First Lien IP Security Agt#page4.tif

source=First Lien IP Security Agt#page5.tif

source=First Lien IP Security Agt#page6.tif

source=First Lien IP Security Agt#page7.tif

source=First Lien IP Security Agt#page8.tif

source=First Lien IP Security Agt#page9.tif

source=First Lien IP Security Agt#page10.tif

source=First Lien IP Security Agt#page11.tif

source=First Lien IP Security Agt#page12.tif

source=First Lien IP Security Agt#page13.tif

source=First Lien IP Security Agt#page14.tif

source=First Lien IP Security Agt#page15.tif

source=First Lien IP Security Agt#page16.tif

source=First Lien IP Security Agt#page17.tif

source=First Lien IP Security Agt#page18.tif

source=First Lien IP Security Agt#page19.tif

source=First Lien IP Security Agt#page20.tif

source=First Lien IP Security Agt#page21.tif

source=First Lien IP Security Agt#page22.tif

source=First Lien IP Security Agt#page23.tif

source=First Lien IP Security Agt#page24.tif

source=First Lien IP Security Agt#page25.tif

source=First Lien IP Security Agt#page26.tif

source=First Lien IP Security Agt#page27.tif

source=First Lien IP Security Agt#page28.tif

source=First Lien IP Security Agt#page29.tif

source=First Lien IP Security Agt#page30.tif

source=First Lien IP Security Agt#page31.tif

source=First Lien IP Security Agt#page32.tif

source=First Lien IP Security Agt#page33.tif
source=First Lien IP Security Agt#page34.tif
source=First Lien IP Security Agt#page35.tif
source=First Lien IP Security Agt#page36.tif
source=First Lien IP Security Agt#page37.tif
source=First Lien IP Security Agt#page38.tif
source=First Lien IP Security Agt#page39.tif
source=First Lien IP Security Agt#page40.tif
source=First Lien IP Security Agt#page41.tif
source=First Lien IP Security Agt#page42.tif
source=First Lien IP Security Agt#page43.tif
source=First Lien IP Security Agt#page44.tif
source=First Lien IP Security Agt#page45.tif
source=First Lien IP Security Agt#page46.tif
source=First Lien IP Security Agt#page47.tif

FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT, dated as of June 26, 2007, is made by each of the entities listed on the signature pages hereof (each a "Grantor" and, collectively, the "Grantors"), in favor of General Electric Capital Corporation ("GE Capital"), as administrative agent and collateral agent (in such capacity, together with its successors and permitted assigns, the "Administrative Agent") for the Lenders and the L/C Issuers (as defined in the Credit Agreement referred to below).

WITNESSETH:

WHEREAS, pursuant to the First Lien Credit Agreement, dated as of June 26, 2007 (as amended, restated, supplemented or otherwise modified from time to time, the "Credit Agreement"), among the Borrower, Holdings, the Lenders and the L/C Issuers from time to time party thereto and Administrative Agent, the Lenders and the L/C Issuers have severally agreed to make extensions of credit to the Borrower upon the terms and subject to the conditions set forth therein;

WHEREAS, each Grantor has agreed, pursuant to a First Lien Guaranty and Security Agreement of dated as of June 26, 2007 herewith in favor of the Administrative Agent (the "Guaranty and Security Agreement"), to guarantee the Obligations (as defined in the Credit Agreement) of the other Loan Parties; and

WHEREAS, all of the Grantors are party to the Guaranty and Security Agreement pursuant to which the Grantors are required to execute and deliver this Intellectual Property Security Agreement.

NOW, THEREFORE, in consideration of the premises and to induce the Lenders, the L/C Issuers and the Administrative Agent to enter into the Credit Agreement and to induce the Lenders and the L/C Issuers to make or continue to make their respective extensions of credit to the Borrower thereunder, each Grantor hereby agrees with the Administrative Agent as follows:

Section 1. Defined Terms. Capitalized terms used herein without definition are used as defined in the Guaranty and Security Agreement.

Section 2. Grant of Security Interest in Intellectual Property Collateral. Each Grantor, as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations on the terms set forth in the Loan Documents, hereby mortgages, pledges and hypothecates to the Administrative Agent, for the benefit of the Secured Parties, and grants to the Administrative Agent, for the benefit of the Secured Parties, a Lien on and security interest in, all of its right, title and interest in, to and under the following Collateral of such Grantor (the "Intellectual Property Collateral"):

(a) Copyrights.

(i) all of its Copyrights and registrations and applications for registration thereof and all registered IP Licenses and applications therefor providing for

the grant to such Grantor of any right under any Copyright, including, without limitation, those referred to on Schedule 1A hereto;

(ii) all renewals, reversions and extensions of the foregoing;

(iii) all income, royalties, proceeds and Liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof, other than, in the case of clauses (i) through (iii), with respect to Excluded Property.

(b) Patents.

(i) all of its registered Patents and applications for registration thereof and all registered IP Licenses and applications therefor providing for the grant to such Grantor of any right under any Patent, including, without limitation, those referred to on Schedule 1B hereto;

(ii) all reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of the foregoing;

(iii) all income, royalties, proceeds and Liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof, other than, in the case of clauses (i) through (iii), with respect to Excluded Property.

(c) Trademarks.

(i) all of its Trademarks and applications for registration thereof and all registered IP Licenses and applications therefor providing for the grant to such Grantor of any right under any Trademark, including, without limitation, those referred to on Schedule 1C hereto;

(ii) all renewals and extensions of the foregoing;

(iii) all goodwill of the business connected with the use of, and symbolized by, each such Trademark; and

(iv) all income, royalties, proceeds and Liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof, other than, in the case of clauses (i) through (iii), with respect to Excluded Property.

Section 3. Guaranty and Security Agreement. The security interest granted pursuant to this Intellectual Property Security Agreement is granted in conjunction with the security interest granted to the Administrative Agent pursuant to the Guaranty and Security Agreement and each Grantor hereby acknowledges and agrees that the rights and remedies of the Administrative Agent with respect to the security interest in the Intellectual Property Collateral

made and granted hereby are more fully set forth in the Guaranty and Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

Section 4. Grantor Remains Liable. Each Grantor hereby agrees that, anything herein to the contrary notwithstanding, such Grantor shall assume full and complete responsibility for the prosecution, defense, enforcement or any other necessary or desirable actions in connection with such Grantor's Intellectual Property Collateral and IP Licenses subject to a security interest hereunder.

Section 5. Counterparts. This Intellectual Property Security Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart.


Section 6. Governing Law. This Intellectual Property Security Agreement and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with, the law of the State of New York.

[SIGNATURE PAGES FOLLOW]

IN WITNESS WHEREOF, each Grantor has caused this Intellectual Property Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

IM US HOLDINGS, LLC
INVERNESS MEDICAL INNOVATIONS, INC.
ADVANTAGE DIAGNOSTICS CORPORATION
APPLIED BIOTECH, INC.
BINAX, INC.
FIRST CHECK DIAGNOSTICS CORP.
FOREFRONT DIAGNOSTICS, INC.
INCA ACQUISITION, INC.
INNOVATIVE MOBILITY, LLC
INSTANT TECHNOLOGIES, INC.
INVERNESS MEDICAL - BIOSTAR, INC.
INVERNESS MEDICAL INTERNATIONAL HOLDING CORP.
INVERNESS MEDICAL INTERNATIONAL HOLDING CORP. II
INNOVATIONS RESEARCH, LLC
INVERNESS MEDICAL, LLC
ISCHEMIA TECHNOLOGIES, INC.
IVC INDUSTRIES, INC.
INNOVACON, INC.
OSTEX INTERNATIONAL, INC.
QUALITY ASSURED SERVICES, INC.
SELF CARE TECHNOLOGY, INC.
SPDH, INC.
UNIPATH ONLINE, INC.
WAMPOLE LABORATORIES, LLC, as Grantors

Approved
As To Form

By: 
Name: David Teitel


Legal Department

Title: President, Chief Financial Officer & Treasurer,
Vice President, Finance, Vice President, Vice
President, Finance, Vice President, Finance,
Vice President, Treasurer, Chief Financial
Officer, Vice President, Finance, Vice President,
Finance, President, President, Vice
President, Finance, Vice President, Finance,
Vice President, Finance, Vice President,
Finance, Vice President, Finance, Vice
President, Finance, Chief Financial Officer, Vice
President, Finance, President, Vice
President, Vice President


[SIGNATURE PAGE TO FIRST LIGI IP SECURITY AGREEMENT]

LEGAL_US_B # 75504384

TRADEMARK
REEL: 003575 FRAME: 0234

ACCEPTED AND AGREED
as of the date first above written:

GENERAL ELECTRIC CAPITAL CORPORATION,
as Administrative Agent

By: 
Name: Andrew D. Moore
Title: Duly Authorized Signatory

[SIGNATURE PAGE TO FIRST LIEN IP SECURITY AGREEMENT]

LEGAL_US_E # 75504384

**SCHEDULE 1A
TO
INTELLECTUAL PROPERTY SECURITY AGREEMENT**

A. COPYRIGHTS

None.

B. COPYRIGHT APPLICATIONS

None.

C. IP LICENSES

None.

**SCHEDULE 1B
TO
FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

A. REGISTERED PATENTS

[Include Owner, Registration Number and Date]

B. PATENT APPLICATIONS

[Include Owner, Application Number and Date]

C. REGISTERED IP LICENSES AND ANY APPLICATIONS THEREFOR

[Include complete legal description of agreement (name of agreement, parties and date)]

[FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT]

File Number	Country	Filing date	Filing number	Grant date	Grant number	List of Owners or Assignees	Expiry
IM0088	AT	19/MAR/2004	GM9005/2004			Advantage Diagnostics Corporation	19/MAR/2014
IM0089	AU	19/MAR/2004	2004/254558			Advantage Diagnostics Corporation	19/MAR/2024
IM0089	BR	19/MAR/2004	P10411059.5			Advantage Diagnostics Corporation	19/MAR/2014
IM0089	CA	19/MAR/2004	2528108			Advantage Diagnostics Corporation	19/MAR/2024
IM0089	CN	19/MAR/2004	2004/800/15772.7			Advantage Diagnostics Corporation	19/MAR/2014
IM0089	CZ	19/MAR/2004	2005-171219	10/APR/2006	16422	Advantage Diagnostics Corporation	19/MAR/2014
IM0089	DE	19/MAR/2004	212004/00032.5	06/APR/2006	212004/00032.5	Advantage Diagnostics Corporation	19/MAR/2014
IM0089	DK	19/MAR/2004	BA2005/02390	13/APR/2007	DK2005/02390	Advantage Diagnostics Corporation	19/MAR/2024
IM0089	EP	19/MAR/2004	04785762.8			Advantage Diagnostics Corporation	19/MAR/2024
IM0089	HK	19/MAR/2004	06106552.1			Advantage Diagnostics Corporation	19/MAR/2024
IM0089	JP	19/MAR/2004	2006-503248			Advantage Diagnostics Corporation	19/MAR/2019
IM0089	KR	19/MAR/2004	20-2005-7900007			Advantage Diagnostics Corporation	19/MAR/2014
IM0089	MX	19/MAR/2004	PA/0/2005/000303			Advantage Diagnostics Corporation	19/MAR/2024
IM0089	PT	19/MAR/2004	2005/003732	27/NOV/2006	58717	Advantage Diagnostics Corporation	19/MAR/2012
IM0089	RU	19/MAR/2004	2005/138919	15/JAN/2007	19871	Advantage Diagnostics Corporation	19/MAR/2014
IM0089	UA	19/MAR/2004	2005/12159/M			Advantage Diagnostics Corporation	06/JUN/2023
IM0089	US	06/JUN/2003	10456771			Applied Biotech, Inc.	23/JUL/2022
AB10005	CA	23/JUL/2002	2455404			Applied Biotech, Inc.	27/OCT/2020
IM0079	US	02/JUN/2003	10453317	22/AUG/2000	6106732	Binax, Inc.	16/APR/2018
BNX0001	US	16/APR/1998	09/06/0855	15/APR/2003	65443308	Binax, Inc.	19/MAR/2018
BNX0002	US	19/MAR/1998	09/04/4677	30/JAN/2003	759633	Binax, Inc.	25/AUG/2019
BNX0003	AU	25/AUG/1999	56933/99	17/OCT/2006	2342141	Binax, Inc.	25/AUG/2019
BNX0003	CA	25/AUG/1999	2342141	28/JAN/2004	98810035.8	Binax, Inc.	25/AUG/2019
BNX0003	CN	25/AUG/1999	98810035.8	03/JAN/2007	1107773	Binax, Inc.	25/AUG/2019
BNX0003	EP	25/AUG/1999	98943841.7			Binax, Inc.	25/AUG/2019
BNX0003	JP	25/AUG/1999	2000-563504			Binax, Inc.	25/AUG/2019
BNX0003	MX	25/AUG/1999	PA/ai/2001/002057	03/APR/2007	244714	Binax, Inc.	25/AUG/2018
BNX0003	US	25/AUG/1999	08/139720			Binax, Inc.	20/SEP/2019
BNX0004	AT	20/SEP/1999	98944850.0	20/APR/2005	E293457	Binax, Inc.	20/SEP/2019
BNX0004	AU	20/SEP/1999	61513199	24/JUL/2003	759329	Binax, Inc.	20/SEP/2019
BNX0004	BE	20/SEP/1999	98944850.0	20/APR/2005	1113817	Binax, Inc.	20/SEP/2019
BNX0004	CA	20/SEP/1999	23422783			Binax, Inc.	20/SEP/2019
BNX0004	CH	20/SEP/1999	98944850.0	20/APR/2005	1113817	Binax, Inc.	20/SEP/2019
BNX0004	CN	20/SEP/1999	98811042.6	17/AUG/2005	98811042.6	Binax, Inc.	20/SEP/2019
BNX0004	DE	20/SEP/1999	98944850.0	20/APR/2005	1113817	Binax, Inc.	20/SEP/2019
BNX0004	DK	20/SEP/1999	98944850.0	20/APR/2005	1113817	Binax, Inc.	20/SEP/2019
BNX0004	EP	20/SEP/1999	98944850.0	20/APR/2005	1113817	Binax, Inc.	20/SEP/2019
BNX0004	ES	20/SEP/1999	98944830.0	20/APR/2005	1113817	Binax, Inc.	20/SEP/2019
BNX0004	FI	20/SEP/1999	98944830.0	20/APR/2005	1113817	Binax, Inc.	20/SEP/2019
BNX0004	FR	20/SEP/1999	98944830.0	20/APR/2005	1113817	Binax, Inc.	20/SEP/2019
BNX0004	GB	20/SEP/1999	98944830.0	20/APR/2005	1113817	Binax, Inc.	20/SEP/2019
BNX0004	IE	20/SEP/1999	98944830.0	20/APR/2005	1113817	Binax, Inc.	20/SEP/2019
BNX0004	IT	20/SEP/1999	98944830.0	20/APR/2005	1113817	Binax, Inc.	20/SEP/2019
BNX0004	JP	20/SEP/1999	2000-573764			Binax, Inc.	20/SEP/2019
BNX0004	MX	20/SEP/1999	PA/ai/2001/002622	17/NOV/2005	232213	Binax, Inc.	20/SEP/2019
BNX0004	NL	20/SEP/1999	98944830.0	20/APR/2005	1113817	Binax, Inc.	20/SEP/2019
BNX0004	PT	20/SEP/1999	98944830.0	20/APR/2005	1113817	Binax, Inc.	20/SEP/2019

SE	BNX0004	20/SEP/1999	99948305.0	20/APR/2005	1113617	Binax, Inc.
US	BNX0004	16/SEP/1999	09/397/110	30/NOV/2004	6824997	Binax, Inc.
US	BNX0005	19/NOV/1999	09/444/211	27/APR/2004	672/073	Binax, Inc.
US	BNX0006	11/DEC/2000	24293/01	16/MAR/2006	783/77	Binax, Inc.
AU	BNX0006	11/DEC/2000	23986/28			Binax, Inc.
CA	BNX0006	11/DEC/2000	00988/037.8			Binax, Inc.
EP	BNX0006	10/DEC/1998	09/453/998			Binax, Inc.
US	BNX0006	01/MAR/2001	2001/24/1667	01/SEP/2005	2001/24/1667	Binax, Inc.
AU	BNX0007	19/AUG/2002	24276/93			Binax, Inc.
CA	BNX0007	01/MAR/2001	019/13/17.70			Binax, Inc.
EP	BNX0007	01/MAR/2001	2001-553/134			Binax, Inc.
JP	BNX0007	01/MAR/2000	09/5/18/165			Binax, Inc.
US	BNX0008	15/JAN/2002	10/044/20			Binax, Inc.
US	BNX0008	07/DEC/2005	1/1/295/486			Binax, Inc.
US	BNX0009	27/FEB/2002	10/083/476			Binax, Inc.
US	BNX0011	24/FEB/2004	2004/21/189			Binax, Inc.
AU	BNX0011	24/FEB/2004	25/165/46			Binax, Inc.
CA	BNX0011	24/FEB/2004	2004/00/045.4			Binax, Inc.
CN	BNX0011	24/FEB/2004	04/714/10.6			Binax, Inc.
EP	BNX0011	24/FEB/2004	06/105/885.0			Binax, Inc.
HK	BNX0011	24/FEB/2004	2006-503/810			Binax, Inc.
JP	BNX0011	24/APR/2004	10/784/155			Binax, Inc.
US	BNX0011	28/JUL/2005	2005/10/34/709.5			Binax, Inc.
CN	BNX0012	16/NOV/2004	10/989/050			Binax, Inc.
US	BNX0012	23/MAY/2007	11/740/738			Binax, Inc.
US	BNX0012	08/DEC/2006	60/1873/855			Binax, Inc.
US	BNX0015	08/AUG/2006	60/1836/200			Binax, Inc.
US	BNX0016	01/MAR/2005	2005/8/0/13856.1			Binax, Inc.
CN	BNX0018	01/MAR/2005	05/724/013.8			Binax, Inc.
EP	BNX0018	26/NOV/2003	2003/295/951			Binax, Inc.
AU	BNX0019	26/NOV/2003	254/1135			Binax, Inc.
CA	BNX0019	16/NOV/2003	2003/801/10715.2			Binax, Inc.
CN	BNX0019	17/FEB/2005	03/8/16/6.2			Binax, Inc.
EP	BNX0019	26/NOV/2003	1786/KOLNP/2006			Binax, Inc.
IN	BNX0019	17/FEB/2005	2005-512/837			Binax, Inc.
JP	BNX0019	26/NOV/2003	PCT/US2003/0137787			Binax, Inc.
NZ	BNX0019	16/NOV/2004	10/989/973			Binax, Inc.
US	BNX0019	17/FEB/2005	2005/80/009058.1			Binax, Inc.
CN	BNX0020	17/FEB/2005	05/807/858.5			Binax, Inc.
EP	BNX0020	17/FEB/2005	11/06/22/1			Binax, Inc.
US	BNX0020	17/FEB/2005	PCT/US2005/005038			Binax, Inc.
US	BNX0021	17/FEB/2005	2005/80/10381.6			Binax, Inc.
CN	BNX0021	17/FEB/2005	05/723/144.1			Binax, Inc.
EP	BNX0021	17/FEB/2005	PCT/US2005/004886			Binax, Inc.
IN	BNX0021	17/FEB/2005	2006-554/175			Binax, Inc.
JP	BNX0021	17/FEB/2005	11/06/01/13			Binax, Inc.
US	BNX0021	17/FEB/2005	11/06/01/13			Binax, Inc.
CN	BNX0022	06/OCT/2005	PCT/US2005/035967			Binax, Inc.

BNX0022	EP	06/OCT/2005	PCTIUS2005/035967	Binax, Inc.
BNX0022	IN	06/OCT/2005	PCTIUS2005/035967	Binax, Inc.
BNX0022	JP	06/OCT/2005	PCTIUS2005/035967	Binax, Inc.
BNX0022	US	06/OCT/2005	11/244996	Binax, Inc.
BNX0026	US	08/DEC/2006	60/873741	Binax, Inc.
BNX0027	US	05/JAN/2007	60/678750	Binax, Inc.
BNX0028	US	20/OCT/2006	60/853264	Binax, Inc.
BNX0029	US	17/JAN/2007	60/880791	Binax, Inc.
BNX0033	US	10/APR/2007	60/910904	Binax, Inc.
BNX0023	US	02/SEP/2003	10/1653321	Binax, Inc.
AB10006	CA	22/MAY/2002	2403151	Forefront Diagnostics, Inc.
BST0001	AU	07/DEC/2000	20769101	Forefront Diagnostics, Inc.
BST0001	CN	07/DEC/2000	0081703.7	Inverness Medical - BioStar Inc.
BST0001	DE	07/DEC/2000	00984071.1	Inverness Medical - BioStar Inc.
BST0001	EP	07/DEC/2000	00984071.1	Inverness Medical - BioStar Inc.
BST0001	FR	07/DEC/2000	00984071.1	Inverness Medical - BioStar Inc.
BST0001	GB	07/DEC/2000	00984071.1	Inverness Medical - BioStar Inc.
BST0001	JP	07/DEC/2000	2001-54519	Inverness Medical - BioStar Inc.
BST0001	KR	07/DEC/2000	2002-7007547	Inverness Medical - BioStar Inc.
BST0001	TW	07/MAR/2001	89126738	Inverness Medical - BioStar Inc.
BST0001	US	14/DEC/2000	09/737635	Inverness Medical - BioStar Inc.
BST0001	US	15/APR/2002	10/123750	Inverness Medical - BioStar Inc.
BST0002	TW	09/JAN/2001	89115794	Inverness Medical - BioStar Inc.
BST0004	DE	20/MAR/1991	91910056.0	18/SEP/1996 6912225.5
BST0004	EP	20/MAR/1991	91910056.0	18/SEP/1996 0539383
BST0004	ES	20/MAR/1991	91910056.0	18/SEP/1996 0539383
BST0004	FR	20/MAR/1991	91910056.0	18/SEP/1996 0539383
BST0004	GB	20/MAR/1991	91910056.0	18/SEP/1996 0539383
BST0004	HK	20/MAR/1991	97102308.7	24/APR/1996 1000735
BST0004	IT	20/MAR/1991	91910056.0	18/SEP/1996 0539383
BST0004	JP	20/MAR/1991	509344/1	25/MAY/2001 3193373
BST0004	DE	18/SEP/1990	90914815.1	26/FEB/1997 5903034.2
BST0005	EP	18/SEP/1990	90914815.1	26/FEB/1997 0493484
BST0005	FR	18/SEP/1990	90914815.1	26/FEB/1997 0493484
BST0005	GB	18/SEP/1990	90914815.1	26/FEB/1997 0493484
BST0005	HK	18/SEP/1990	97102316.7	26/APR/1998 1000736
BST0005	IT	18/SEP/1990	90914815.1	26/FEB/1997 0493484
BST0005	JP	18/SEP/1990	2-513789	21/AUG/1996 2818292
BST0005	JP	18/SEP/1990	10-5911	09/JUL/1999 2951300
BST0005	US	31/JUL/1992	07/823304	21/NOV/1995 5468606
BST0005	US	28/MAR/1995	08/412660	17/JUN/1997 5639671
BST0005	DE	11/FEB/1992	92900299.0	18/SEP/2010 0524301
BST0005	EP	11/FEB/1992	92900299.0	18/SEP/2010 0524301
BST0005	ES	11/FEB/1992	92900299.0	18/SEP/2010 0524301
BST0005	FR	11/FEB/1992	92900299.0	18/SEP/2010 0524301
BST0005	GB	11/FEB/1992	92900299.0	18/SEP/2010 0524301
BST0005	HK	11/FEB/1992	98100895.9	21/MAR/2003 1001859

BST0006	IT	JP	11/FEB/1992	92906299.0	24/JUL/2002	0524301	Inverness Medical - Biostar Inc.
BST0006	JP	11/FEB/1992	505739/92	2001-312846	28/JUL/2006	3833507	Inverness Medical - Biostar Inc.
BST0006	JP	16/SEP/2003	2003-323351	27/AUG/1996	5550063	Inverness Medical - Biostar Inc.	
BST0006	US	10/JUN/1993	08/076247	25/NOV/1998	69227655.6	Inverness Medical - Biostar Inc.	
BST0006	DE	11/FEB/1992	92907304.7	25/NOV/1998	0525178	Inverness Medical - Biostar Inc.	
BST0007	EP	11/FEB/1992	92907304.7	25/NOV/1998	0525178	Inverness Medical - Biostar Inc.	
BST0007	ES	11/FEB/1992	92907304.7	25/NOV/1998	0525178	Inverness Medical - Biostar Inc.	
BST0007	FR	11/FEB/1992	92907304.7	25/NOV/1998	0525178	Inverness Medical - Biostar Inc.	
BST0007	GB	11/FEB/1992	92907304.7	25/NOV/1998	0525178	Inverness Medical - Biostar Inc.	
BST0007	HK	08/100899.5	88100899.5	24/MAR/2000	1001890	Inverness Medical - Biostar Inc.	
BST0007	IT	11/FEB/1992	92907304.7	25/NOV/1998	0525178	Inverness Medical - Biostar Inc.	
BST0008	BE	01/OCT/1991	91308968.6	10/SEP/1997	0546222	Inverness Medical - Biostar Inc.	
BST0008	DE	01/OCT/1991	91308968.6	10/SEP/1997	0546222	Inverness Medical - Biostar Inc.	
BST0008	EP	01/OCT/1991	91308968.6	10/SEP/1997	0546222	Inverness Medical - Biostar Inc.	
BST0008	ES	01/OCT/1991	91308968.6	10/SEP/1997	0546222	Inverness Medical - Biostar Inc.	
BST0008	FR	01/OCT/1991	91308968.6	10/SEP/1997	0546222	Inverness Medical - Biostar Inc.	
BST0008	GB	01/OCT/1991	91308968.6	10/SEP/1997	0546222	Inverness Medical - Biostar Inc.	
BST0008	HK	01/OCT/1991	91308968.6	24/APR/1998	1000771	Inverness Medical - Biostar Inc.	
BST0008	JP	24/SEP/1992	198609/98	08/SEP/2000	3107787	Inverness Medical - Biostar Inc.	
BST0008	JP	24/SEP/1992	254562/92	02/OCT/1998	2834950	Inverness Medical - Biostar Inc.	
BST0009	US	10/JUN/1993	08/076320	08/JAN/1996	5482530	Inverness Medical - Biostar Inc.	
BST0009	US	17/APR/1995	08/403565	21/AUG/1999	5955377	Inverness Medical - Biostar Inc.	
BST0009	US	31/MAY/1995	08/456040	13/MAY/1997	5629214	Inverness Medical - Biostar Inc.	
BST0009	US	31/MAY/1995	08/455632	09/FEB/1999	5869272	Inverness Medical - Biostar Inc.	
BST0010	US	10/JUN/1993	08/076719	23/MAY/1995	5418136	Inverness Medical - Biostar Inc.	
BST0011	EP	01/108521.4	10/JUN/1993	23/MAY/2007	1126278	Inverness Medical - Biostar Inc.	
BST0011	EP	10/JUN/1993	93915244.7	14/DEC/2005	0727038	Inverness Medical - Biostar Inc.	
BST0011	EP	10/JUN/1993	05027236.8	14/DEC/2005	0727038	Inverness Medical - Biostar Inc.	
BST0011	GB	10/JUN/1993	93915341.7	23/MAY/2007	1126278	Inverness Medical - Biostar Inc.	
BST0011	GB	10/JUN/1993	01108521.4	13/OCT/2006	1003304	Inverness Medical - Biostar Inc.	
BST0011	HK	98102353.0	10/JUN/1993	10/JUN/1993	2001-23693	Inverness Medical - Biostar Inc.	
BST0011	JP	10/JUN/1993	93915344.7	01/AUG/2003	3456984	Inverness Medical - Biostar Inc.	
BST0011	JP	10/JUN/1993	2001-236166	26/DEC/2003	3506703	Inverness Medical - Biostar Inc.	
BST0011	JP	10/JUN/1993	2001-236411	31/MAR/2006	3787143	Inverness Medical - Biostar Inc.	
BST0011	JP	10/JUN/1993	1994-50280	23/APR/2004	3847723	Inverness Medical - Biostar Inc.	
BST0011	JP	10/JUN/1993	276389/2004	26/DEC/2003	3507048	Inverness Medical - Biostar Inc.	
BST0011	JP	03/AUG/2001	2001-236198	27/FEB/1996	5494829	Inverness Medical - Biostar Inc.	
BST0011	JP	03/AUG/2001	2001-236186	20/MAY/1997	5631171	Inverness Medical - Biostar Inc.	
BST0011	US	10/JUN/1993	08/076348	09/MAY/2000	6060237	Inverness Medical - Biostar Inc.	
BST0011	US	31/MAY/1995	08/455493	12/MAR/2002	6365429	Inverness Medical - Biostar Inc.	
BST0013	US	20/MAR/1995	08/1619961	31/AUG/2004	6783938	Inverness Medical - Biostar Inc.	
BST0020	US	17/JAN/1995	08/375151	03/SEP/1996	6552272	Inverness Medical - Biostar Inc.	
BST0020	US	21/OCT/1999	09/425072	30/JUL/1997	6551057	Inverness Medical - Biostar Inc.	
BST0020	US	18/OCT/2001	09/982658	30/JUL/1996	6943446.0	Inverness Medical - Biostar Inc.	
BST0021	US	10/JUN/1993	08/076348	02/DEC/2014	02/DEC/2014	Inverness Medical - Biostar Inc.	
BST0022	US	10/JUN/1993	08/075952	02/DEC/2014	02/DEC/2014	Inverness Medical - Biostar Inc.	
BST0023	DE						

BST0023	EP	02/DEC/1994	94308983.9	15/JUN/2005	0659437
BST0023	ES	02/DEC/1994	94308983.9	15/JUN/2005	0659437
BST0023	FR	02/DEC/1994	94308983.9	15/JUN/2005	0659437
BST0023	GB	02/DEC/1994	94308983.9	15/JUN/2005	0659437
BST0023	HK	02/DEC/1994	94308983.9	23/SEP/2005	1001885
BST0023	IT	02/DEC/1994	98100898.6	15/JUN/2005	0659437
BST0023	US	03/DEC/1993	08116240.1	27/FEB/1996	5494801
BST0024	AU	21/JUN/1999	49603/99	26/SEP/2002	747986
BST0024	CA	21/JUN/1999	2334584	03/MAY/2005	2334584
BST0024	CN	21/JUN/1999	99806819.5	07/APR/2004	99806819.5
BST0024	DE	21/JUN/1999	99933568.0	12/NOV/2003	1089800
BST0024	EP	21/JUN/1999	99933568.0	12/NOV/2003	1089800
BST0024	ES	21/JUN/1999	99933568.0	12/NOV/2003	1089800
BST0024	FR	21/JUN/1999	99933568.0	12/NOV/2003	1089800
BST0024	GB	21/JUN/1999	99933568.0	12/NOV/2003	1089800
BST0024	HK	21/JUN/1999	01107099.4	30/SEP/2004	1036236
BST0024	IN	21/JUN/1999	IN/PC/T/2000/00662	12/NOV/2003	1089800
BST0024	IT	21/JUN/1999	99933568.0	12/NOV/2003	1089800
BST0024	JP	21/JUN/1999	2004-297557	16/FEB/2007	3916869
BST0024	JP	21/JUN/1999	2003-556849	28/JAN/2006	121411A
BST0024	MY	22/JUN/1999	P19902560	15/JUN/2003	78192
BST0024	SG	21/JUN/1999	2003067449.8	20/FEB/2001	NL-121230
BST0024	TW	24/JUN/1999	88110661	18/JUL/2000	6080572
BST0024	US	28/JUN/1998	091105309	27/MAR/2001	6207445
BST0024	US	17/JUL/2000	091617394	20/AUG/2004	772655
BST0025	AU	06/MAR/2000	37271/00		
BST0025	CA	06/MAR/2000	23665/07		
BST0025	CN	06/MAR/2000	00805077.5		
BST0025	EP	06/MAR/2000	0091614.2		
BST0025	HK	06/MAR/2000	02104875.0	02/JUN/2006	199289
BST0025	IN	06/MAR/2000	IN/PC/T/2001/00958		
BST0025	JP	06/MAR/2000	2000-605207		
BST0025	KR	06/MAR/2000	10-200171843	19/JAN/2007	0674525
BST0025	SG	06/MAR/2000	200105414.7	28/NOV/2003	83390
BST0025	TW	06/APR/2000	89104986	11/DEC/2001	NL-146428
BST0025	US	18/MAR/1999	091272641	11/SEP/2001	6287783
BST0025	US	12/JUL/2001	091905146	03/AUG/2004	6770447
BST0026	CN	03/AUG/2000	008122024		
BST0026	EP	03/AUG/2000	00952567.6		
BST0026	JP	03/AUG/2000	2001-515978	30/JUN/2006	3823053
BST0026	JP	03/AUG/2000	2005-373906	23/JAN/2007	0675698
BST0026	KR	03/AUG/2000	10-2002-7001601	11/JAN/2003	NL-169801
BST0026	TW	26/SEP/2000	89115787	02/DEC/2003	6656128
BST0026	US	03/AUG/2000	091632343	09/AUG/2001	732463
BST0027	AU	20/OCT/1997	49129/97	20/OCT/1997	97911850.2
BST0027	EP	20/OCT/1997	99105268.6	20/OCT/1997	W-990278
BST0027	HK	20/OCT/1997	99105268.6	22/DEC/2003	ID0012334
BST0027	ID	20/OCT/1997	W-990278	20/OCT/2017	20/OCT/2017

20/OCT/1997	1998-5205667	Inverness Medical - Biostar Inc.
JP	BST0027	23/APR/2004 3547454
JP	BST0027	12/JAN/2007 3900289
TW	BST0027	21/JUN/2004 NI-205664
US	BST0027	26/DEC/2004 7153651
US	BST0027	23/AUG/2005 6933112
US	BST0027	03/JUN/2004 770194
AU	BST0028	17/DEC/1999 2194100
CN	BST0028	17/DEC/1999 998150967.6
CN	BST0028	17/DEC/1999 998150967.7
HK	BST0028	17/DEC/1999 998150967.5
IN	BST0028	17/DEC/1999 02100371.7
JP	BST0028	28/1/DEL/NP/2006
JP	BST0028	17/DEC/1999 2005-328455
NY	BST0028	21/DEC/1999 PI9056641
SG	BST0028	17/DEC/1999 200103852.0
TW	BST0028	17/DEC/1999 88122268
US	BST0028	29/DEC/1998 09/230666
CN	BST0030	03/AUG/2000 0081055.7
CN	BST0030	03/AUG/2000 200510035540.5
EP	BST0030	03/AUG/2000 00933853.9
IN	BST0030	03/AUG/2000 IN/PCT/2002/00161
JP	BST0030	03/AUG/2000 2004-219193
JP	BST0030	03/AUG/2000 2004-515920
KR	BST0030	03/AUG/2000 10-2002-7001557
US	BST0030	04/AUG/2000 09/6333036
CN	BST0032	14/APR/2004 2004480010302.1
EP	BST0032	14/APR/2004 04750150.7
HK	BST0032	14/APR/2004 06102354.0
IN	BST0032	14/APR/2004 37511/DEL/NP/2005
JP	BST0032	14/APR/2004 2006-510051
KR	BST0032	14/APR/2004 10-2005-7019594
US	BST0032	16/APR/2003 10/417883
ES	BSTD0029	21/SEP/1999 1463394
JP	BSTD0029	22/MAR/1999 11-025661
US	BSTD0029	02/OCT/2003 10/680935
US	BSTD0029	02/OCT/2003 10/679699
US	BSTD0029	02/OCT/1998 09/165926
US	BSTD0029	02/OCT/1998 09/165561
AT	ISC0005	10/JUL/1992 10/9161997
US	ISC0005	10/JUL/1992 10/661997
BE	ISC0005	10/JUL/1992 92915653.8
BR	ISC0005	10/JUL/1992 P19203312.8
CA	ISC0005	10/JUL/1992 2113266
CH	ISC0005	10/JUL/1992 92915653.8
DE	ISC0005	10/JUL/1992 92915653.3
DK	ISC0005	10/JUL/1992 92915653.8
EP	ISC0005	10/JUL/1992 92915653.8
EP	ISC0005	03027486.4

TRADEMARK
REEL: 003575 FRAME: 0243

ISC0005	ES	10/JUL/1992	92915563.8	09/MAR/2005	0596925	Ischemia Technologies, Inc.
ISC0005	FR	10/JUL/1992	92915563.8	09/MAR/2005	0596925	Ischemia Technologies, Inc.
ISC0005	GB	10/JUL/1992	92915563.8	09/MAR/2005	0596925	Ischemia Technologies, Inc.
ISC0005	GR	10/JUL/1992	92915563.8	09/MAR/2005	3053499	Ischemia Technologies, Inc.
ISC0005	IE	24/JUL/1992	1892/24/21	18/FEB/2006	84165	Ischemia Technologies, Inc.
ISC0005	IE	02/AUG/2005	2005/05/15	09/MAR/2005	0596925	Ischemia Technologies, Inc.
ISC0005	IT	10/JUL/1992	92915563.8	09/MAR/2005	0596925	Ischemia Technologies, Inc.
ISC0005	JP	10/JUL/1992	503561/93	01/JUN/2001	3194952	Ischemia Technologies, Inc.
ISC0005	KR	10/JUL/1992	700225/1994	23/OCT/1998	239947	Ischemia Technologies, Inc.
ISC0005	LU	10/JUL/1992	92915563.8	09/MAR/2005	0596925	Ischemia Technologies, Inc.
ISC0005	MC	10/JUL/1992	92915563.8	09/MAR/2005	0596925	Ischemia Technologies, Inc.
ISC0005	NL	10/JUL/1992	92915563.8	09/MAR/2005	0596925	Ischemia Technologies, Inc.
ISC0005	NO	10/JUL/1992	1994/02/56	16/DEC/2002	313960	Ischemia Technologies, Inc.
ISC0005	PT	24/JUL/1992	10/07/24	14/APR/1998	100724	Ischemia Technologies, Inc.
ISC0005	SE	10/JUL/1992	92915563.8	09/MAR/2005	0596925	Ischemia Technologies, Inc.
ISC0005	US	26/JUL/1991	07/7365/83	13/JUL/1993	52227307	Ischemia Technologies, Inc.
ISC0005	US	12/FEB/1993	08/0169/71	01/MAR/1994	52805019	Ischemia Technologies, Inc.
ISC0005	EP	01/OCT/1999	9995/0055/6	05/NOV/2002	6475743	Ischemia Technologies, Inc.
ISC0006	US	02/OCT/1998	09/1659/61	04/JUL/2006	7070937	Ischemia Technologies, Inc.
ISC0006	US	29/MAR/2001	09/8204/16			Ischemia Technologies, Inc.
ISC0006	US	30/AUG/2002	10/2323/41			Ischemia Technologies, Inc.
ISC0006	US	31/JAN/2005	11/0490/20			Ischemia Technologies, Inc.
ISC0006	US	01/MAY/2002	027345/74.3			Ischemia Technologies, Inc.
ISC0007	EP	01/OCT/1999	9995/0055/6	27/MAY/2004	769727	Ischemia Technologies, Inc.
ISC0007	US	01/OCT/1998	09/1659/61			Ischemia Technologies, Inc.
ISC0010	AU	01/OCT/1999	64095/99			Ischemia Technologies, Inc.
ISC0010	CA	01/OCT/1999	23447/62			Ischemia Technologies, Inc.
ISC0010	EP	01/OCT/1999	9995/17/10.5			Ischemia Technologies, Inc.
ISC0010	JP	01/OCT/1999	2000-57/907			Ischemia Technologies, Inc.
ISC0010	US	15/APR/2003	10/4144/69			Ischemia Technologies, Inc.
ISC0010	US	15/APR/2003	10/4138/52			Ischemia Technologies, Inc.
ISC0010	US	15/APR/2003	10/4143/86			Ischemia Technologies, Inc.
ISC0010	US	15/APR/2003	10/4138/31			Ischemia Technologies, Inc.
ISC0010	US	13/DEC/2002	10/3192/53			Ischemia Technologies, Inc.
ISC0011	US	12/JAN/2005	11/0333/76			Ischemia Technologies, Inc.
ISC0012	AU	26/NOV/2002	200235/2659			Ischemia Technologies, Inc.
ISC0012	CA	26/NOV/2002	2468/236			Ischemia Technologies, Inc.
ISC0012	EP	26/NOV/2002	027839/19.4			Ischemia Technologies, Inc.
ISC0012	JP	26/NOV/2002	2003-54/928			Ischemia Technologies, Inc.
ISC0012	US	01/MAY/2006	11/4159/29	20/JUN/2006	7063782	Ischemia Technologies, Inc.
ISC0012	US	30/APR/2002	200230/5335			Ischemia Technologies, Inc.
ISC0013	CA	30/APR/2002	2446/187			Ischemia Technologies, Inc.
ISC0013	DE	30/APR/2002	027341/4.6	27/DEC/2006	60217/02.4	Ischemia Technologies, Inc.
ISC0013	EP	30/APR/2002	027341/4.6	27/DEC/2006	1392150	Ischemia Technologies, Inc.
ISC0013	FR	30/APR/2002	027341/4.6	27/DEC/2006	1392150	Ischemia Technologies, Inc.
ISC0013	GB	30/APR/2002	027341/4.6	27/DEC/2006	1392150	Ischemia Technologies, Inc.
ISC0013	JP	30/APR/2002	2002-58/6801			Ischemia Technologies, Inc.
ISC0013	US	04/MAY/2001	09/649986			Ischemia Technologies, Inc.

ISC0014	AU	29/APR/2002	2002308530	Ischemia Technologies, Inc.
ISC0014	CA	28/APR/2002	2446329	Ischemia Technologies, Inc.
ISC0014	EP	29/APR/2002	02765865.6	Ischemia Technologies, Inc.
ISC0014	JP	29/APR/2002	2002-585988	Ischemia Technologies, Inc.
ISC0014	US	01/MAY/2001	09/646411	01/MAY/2021
ISC0014	AU	05/MAY/2004	20044240557	05/MAY/2024
ISC0015	CA	05/MAY/2004	2524530	05/MAY/2024
ISC0015	CN	05/MAY/2004	2004480013619.0	05/MAY/2024
ISC0015	EP	05/MAY/2004	04751679.4	05/MAY/2024
ISC0015	HK	05/MAY/2004	06110013.6	05/MAY/2024
ISC0015	IL	05/MAY/2004	171781	05/MAY/2024
ISC0015	IN	05/MAY/2004	2131/KOLNP/2005	05/MAY/2024
ISC0015	JP	05/MAY/2004	2008-532878	05/MAY/2024
ISC0015	KR	05/MAY/2004	2005-7020921	05/MAY/2024
ISC0015	NZ	05/MAY/2004	543538	05/MAY/2024
ISC0015	SG	05/MAY/2004	200507034.7	05/MAY/2024
ISC0015	US	19/MAY/2003	10/441155	14/MAY/2024
ISC0015	US	22/DEC/2005	11/317831	19/MAY/2023
ISC0016	EP	23/JAN/2006	08719258.3	23/JAN/2026
SELF0001	US	10/MAR/1998	29/084813	20/APR/2013
SELF0001	US	24/SEP/1998	094066	04/APR/2000
			20/APR/1999	D408292
			04/APR/2000	D422217
				Selfcare
				Selfcare

**SCHEDULE 1C
TO
FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

A. REGISTERED TRADEMARKS

[Include Owner, Registration Number and Date]

B. TRADEMARK APPLICATIONS

[Include Owner, Application Number and Date]

C. REGISTERED IP LICENSES AND ANY APPLICATIONS THEREFOR

[Include complete legal description of agreement (name of agreement, parties and date)]

[FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT]

**COUNTERPART TO
FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This counterpart, dated as of June 29, 2007, is delivered pursuant to that certain First Lien Intellectual Property Security Agreement dated as of June 26, 2007 (as from time to time amended, modified or supplemented, the "Intellectual Property Security Agreement"; the terms defined therein and not otherwise defined herein being used as therein defined), among each of the Grantors listed on the signature pages thereto and General Electric Capital Corporation, as Agent. The undersigned hereby agrees (i) that this counterpart may be attached to the Intellectual Property Security Agreement, and (ii) that the undersigned will comply with and be subject to, including representations and warranties, all the terms and conditions of the Intellectual Property Security Agreement as if it were an original signatory thereto.

Schedules IA, IB and IC of the Intellectual Property Security Agreement are hereby supplemented with the information relating to the undersigned set forth on Schedules IA, IB and IC hereto, respectively. All references in the Intellectual Property Security Agreement to such Schedules shall be deemed to refer to such Schedules, as supplemented hereby.

[SIGNATURE PAGE FOLLOWS]

BIOSITE INCORPORATED

By: 
Name: David Teitel
Title: Treasurer

Approved
As To Form


Legal Department

[SIGNATURE PAGE TO FIRST LIEN COUNTERPART TO IP SECURITY AGREEMENT]
LEGAL_US_E # 75434690

TRADEMARK
REEL: 003575 FRAME: 0256

SUPPLEMENTAL SCHEDULES
TO
FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT
DATED AS OF JUNE 26, 2007
AMONG
THE GRANTORS PARTY THERETO
AND
GENERAL ELECTRIC CAPITAL CORPORATION,
AS ADMINISTRATIVE AGENT

These Supplemental Schedules are being delivered in connection with the joinder of Biosite Incorporated as a Grantor to the First Lien Guaranty and Security Agreement among the Borrower, the Grantors party thereto and General Electric Capital Corporation, as Administrative Agent dated as of June 26, 2007 (the "*Agreement*"). The Supplemental Schedules (the "*Schedules*") are dated as of June 29, 2007 and give effect to, and contain data relating to, the acquisition by a wholly-owned subsidiary of Inverness Medical Innovations, Inc. of the capital stock of Biosite Incorporated only. Unless otherwise stated, capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Agreement.

The headings contained in the Schedules are included for convenience only and are not intended to limit the effect of the disclosures contained in the Schedules or to expand the scope of the information required to be disclosed in the schedules.

No reference to or listing, description, disclosure or other inclusion of any item or other matter in the Schedules shall be construed to mean that such item or other matter is required to be referred to, listed, described, disclosed or otherwise so included in the Schedules. The reference to or listing, description, disclosure or other inclusion of any item or other matter, including, without limitation, any change, violation, breach, debt, obligation or liability, in the Schedules shall not be construed to be an admission or suggestion that such item or matter constitutes a violation of, breach or default under, any contract, agreement, note, lease or otherwise. No disclosure in the Schedules relating to any possible breach or violation of any agreement, law or regulation shall be construed as an admission or indication that any such breach or violation exists or has actually occurred.

**SCHEDULE 1A
TO
FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

Copyrights - None

**SCHEDULE 1B
TO
FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

See attached list of patents

Title	Inventor	Application No. Filing Date	Patent No. Issue Date
Polypeptides Related to Natriuretic Peptides and Methods of their Identification and Use	Buechler, Kenneth F. Fung, Eric Thomas Yip, Tai-Tung	2522709 04/19/2004	
Polypeptides Related to Natriuretic Peptides and Methods of Their Identification and Use	Buechler, Kenneth F. Fung, Eric Thomas Yip, Tai-Tung	10/827919 04/19/2004	
Human Antibodies	Buechler, Joe Valkirs, Gunars E. Gray, Jeff Lonberg, Nils	09/453234 12/01/1999	6794132 09/21/2004
Human Antibodies	Lonberg, Nils Buechler, Joe Valkirs, Gunars E. Gray, Jeff Valkirs, Gunars E.	10/111365 04/01/2002	7135287 11/14/2006
Human Antibodies	Buechler, Joe Valkirs, Gunars E. Gray, Jeff Valkirs, Gunars E.	11/521060 09/13/2006	
Human Antibodies as Diagnostic Reagents	Buechler, Joe Valkirs, Gunars E. Gray, Jeff Lonberg, Nils	09/456090 12/06/1999	6680209 01/20/2004
Human Antibodies as Diagnostic Reagents	Buechler, Joe Valkirs, Gunars E. Gray, Jeff Lonberg, Nils	10/149737 06/06/2002	7189515 03/13/2007
Human Antibodies as Detection Reagents	Buechler, Joe Valkirs, Gunars E. Gray, Jeff Lonberg, Nils	11/685068 03/12/2007	
Assays and Kits for Detecting Analytes In the Presence of Cross-Reacting Substances	Valkirs, Gunars E.	08/006341 01/19/1993	5914241 06/22/1999
Methods for Concentrating Ligands Using Magnetic Particles	Valkirs, Gunars E.	09/054918 04/03/1998	6348318 02/19/2002
Polyvalent Display Libraries	Buechler, Joe Valkirs, Gunars E. Gray, Jeff	08/832985 04/04/1997	6057098 05/02/2000
Polyvalent Display Libraries	Buechler, Joe Valkirs, Gunars E. Gray, Jeff	09/563055 05/01/2000	6986986 01/17/2006

TRADEMARK

REEL: 003575 FRAME: 0260

Title	Inventor	Application No.	Patent No.
		Filing Date	Issue Date
Polyclonal Libraries	Gray, Jeff Buechler, Joe Valkirs, Gunars E.	08/835159 04/04/1997	6555310 04/29/2003
Diagnostic Tests and Kits for Clostridium Difficile	Valkirs, Gunars E.	08/832935 04/04/1997	5965375 10/12/1999
Diagnostic Tests and Kits for Clostridium Difficile	Valkirs, Gunars E.	09/363960	6503722 01/07/2003
Recombinant Library Screening Methods	Dower, William J. Cwirla, Steven E.	07/517659 05/01/1990	5427908 06/27/1995
Recombinant Library Screening Methods	Dower, William J. Cwirla, Steven E.	08/376326 01/20/1995	5580717 12/03/1996
RECOMBINANT LIBRARY SCREENING METHODS	Dower, William J. Cwirla, Steven E.	08/450754 05/25/1995	
DIAGNOSTIC ASSAY FOR DETECTION OF CRYPTOSPORIDIUM PARVUM	Gray, Jeff Valkirs, Gunars E. Buechler, Joe	09/158180 09/21/1998	
Diagnostic Assays for Detection of Cryptosporidium Parvum	Gray, Jeff Valkirs, Gunars E. Buechler, Joe	09/877933 06/07/2001	7052858 05/30/2006
Diagnostic Assays for Detection of Giardia Lamblia Histolytica	Buechler, Joe Govindaraj, Shanthi Gray, Jeff Valkirs, Gunars E.	10/155163 05/23/2002	6908739 06/21/2005
Diagnostic Assays for Detection of Entamoeba Histolytica	Valkirs, Gunars E. Buechler, Joe Gray, Jeff	09/158347 09/21/1998	6207395 03/27/2001
Chimeric Polyclonal Antibodies	Buechler, Joe Valkirs, Gunars E. Gray, Jeff	09/410903 10/02/1999	6420113 07/16/2002
Chimeric Polyclonal Antibodies	Buechler, Joe	10/193960 07/12/2002	
Use of a Tag to Enrich Polypeptides Libraries	Buechler, Joe Valkirs, Gunars Gray, Jeff		11/015628 12/16/2004
Assays for Detection of Bacillus Anthracis	Lee, Bruce A. Flores, Becky M. Valkirs, Gunars E.	09/754947 01/04/2001	6828110 12/07/2004

Title	Inventor	Application No.	Patent No.
		Filing Date	Issue Date
Assays for Detection of Bacillus Anthracis	Lee, Bruce A. Flores, Becky M. Valkirs, Gunars E.	10/890083 07/12/2004	
Methods for Detecting B. Anthracis Infection	Valkirs, Gunars E. Buechler, Kenneth F.	10/339744 01/08/2003	
Methods for Detecting B. Anthracis Infection	Valkirs, Gunars E. Buechler, Kenneth F.	10/447300 05/27/2003	
Compositions and Methods for Phage Display of Polypeptides	Gray, Jeff Valkirs, Gunars E.	11/198920 08/05/2005	
Latent Protein C Assays and Their Uses for Diagnosis and/or Prognosis in Systemic Inflammatory Response Syndromes	Valkirs, Gunars E. Buechler, Joe	11/614836 12/21/2006	
High Sensitivity Secretagogin Assays and Their Uses for Diagnosis and/or Prognosis	Buechler, Joe Nakamura, Kevin	11/654901 01/17/2007	

TITLE	INVENTORS	CNTRY	SERIAL NO./ FILING DATE	REG NO./ REG. DATE
Devices and Methods for Performing Receptor Binding Assays Using Magnetic Particles	John Michael Anderberg David M. Gregory	USA	60/834,073 07/28/2006	
Methods and Compositions For Monitoring And Risk Prediction in Cardiorenal Syndrome	Gunars Valkirs Paul H. McPherson	USA	60/859,137 11/14/2006	
Methods and compositions for monitoring and risk prediction in cardiorenal syndrome	Gunars Valkirs Paul H. McPherson	USA	60/891,342 02/23/2007	
Method and Compositions for Diagnosis and Prognosis of Renal Artery Stenosis	Gunars Valkirs Paul H. McPherson	USA	60/859,136 11/14/2006	

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	11/512743	8/29/2006			USE OF SOLUBLE FLT-1 AND ITS FRAGMENTS IN CARDIOVASCULAR CONDITIONS
United States of America	11/684498	3/9/2007			METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF DISEASES OF THE AORTA
United States of America	11/752135	5/22/2007			USE OF Natriuretic Peptides AS DIAGNOSTIC AND PROGNOSTIC INDICATORS IN VASCULAR DISEASES
United States of America	07/583738	10/10/1990	5091512	2/25/1992	Fibrinogen-specific monoclonal antibody
United States of America	07/364053	6/8/1989	5120834	6/9/1992	Fibrin-specific monoclonal antibody
United States of America	07/835580	2/14/1992	5223410	6/29/1993	Method for production of antibodies using an antigen-free animal
United States of America	07/295568	1/10/1989	5028535	7/2/1991	THRESHOLD LIGAND-RECEPTOR ASSAY
United States of America	08/284035	8/11/1994	5679526	10/21/1997	THRESHOLD LIGAND-RECEPTOR ASSAY
United States of America	08/871900	6/11/1997	5939272	8/17/1999	NON-COMPETITIVE THRESHOLD LIGAND-RECEPTOR ASSAYS
United States of America	08/458276	6/2/1995	5922615	7/13/1995	DEVICE FOR LIGAND RECEPTOR METHODS
United States of America	09/249321	2/11/1999	6297060	10/22/2001	DEVICE FOR LIGAND RECEPTOR METHODS
United States of America	07/463150	1/10/1990	5089391	2/18/1992	THRESHOLD LIGAND-RECEPTOR ASSAY
United States of America	07/583046	9/14/1990	5143852	9/1/1993	ANTIBODIES TO LIGAND ANALOGUES AND THEIR UTILITY IN LIGAND-RECEPTOR ASSAYS
United States of America	07/808515	12/16/1991	5233042	8/3/1993	NOVEL COCAINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE COCAINE DERIVATIVE CONJUGATES AND LABELS
United States of America	07/884110	4/6/1992	5414085	5/31/1995	NOVEL BARBITURATE DERIVATIVES AND PROTEIN AND POLYPEPTIDE BARBITURATE DERIVATIVE CONJUGATES AND LABELS

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	07/864108	4/6/1992	5470997	11/28/1995	AMPHETAMINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE AMPHETAMINE DERIVATIVE CONJUGATES AND LABELS
United States of America	07/864106	4/6/1992	5237057	8/17/1993	NOVEL TETRAHYDROCANNABINOL DERIVATIVES AND PROTEIN AND POLYPEPTIDE TETRAHYDROCANNABINOL DERIVATIVE CONJUGATES AND LABELS
United States of America	08/325998		3171993	4/12/1994	TETRAHYDROCANNABINOL DERIVATIVES AND PROTEIN AND POLYPEPTIDE TETRAHYDROCANNABINOL DERIVATIVE CONJUGATES AND LABELS
United States of America	07/864093	4/6/1992	5302715	4/12/1994	NOVEL BENZODIAZEPINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE BENZODIAZEPINE DERIVATIVE CONJUGATES AND LABELS
United States of America	07/864104		4/6/1992	5331109	7/19/1994 PHENCYCLIDINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE PHENCYCLIDINE DERIVATIVE CONJUGATES AND LABELS
United States of America	08/241061		5/1/1994	6777190	8/17/2004 CROSSTALK INHIBITORS AND THEIR USES
United States of America	08/101677		8/3/1993	5525524	6/11/1996 CROSSTALK INHIBITORS AND THEIR USES
United States of America	07/887526		5/21/1992	5458852	10/17/1995 DIAGNOSTIC DEVICES FOR THE CONTROLLED MOVEMENT OF A REAGENT WITHOUT MEMBRANES
United States of America	08/447895		5/23/1995	6019944	2/1/2000 DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES

BIOSITE Case Listing

Country	Application Number	Application Date	Patient Number	Grant Date	Title
United States of America	08/447981	5/23/1995	58855327	3/23/1999	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	08/825041	3/27/1997	6156270	12/5/2000	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	08/902775	7/30/1997	6271040	8/7/2001	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	08/810569	3/3/1997	6143576	11/7/2000	NON-POROUS DIAGNOSTIC DEVICES FOR THE CONTROLLED MOVEMENT OF REAGENTS
United States of America	09/613650	7/11/2000			DIAGNOSTIC DEVICES FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	09/805653	3/13/2001	6767510	7/27/2004	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	09/982629	10/18/2001	6905882	6/14/2005	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	10/697351	10/29/2003			DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	10/792258			3/2/2004	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES
United States of America	11/022297			12/22/2004	DIAGNOSTIC DEVICES AND APPARATUS FOR THE CONTROLLED MOVEMENT OF REAGENTS WITHOUT MEMBRANES

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	08/416034	4/3/1995	5710256	1/20/1998	METHADONE DERIVATIVES AND PROTEIN AND POLYPEPTIDE METHADONE DERIVATIVE CONJUGATES AND LABELS
United States of America	07/973997	11/9/1992	6037455	3/14/2000	PROPOXYPHENE DERIVATIVES AND PROTEIN AND POLYPEPTIDE PROPOXYPHENE DERIVATIVE CONJUGATES AND LABELS
United States of America	08/071203	6/7/1993	5480792	1/2/1996	ANTIBODIES TO COMPLEXES OF LIGAND RECEPTORS AND LIGANDS AND THEIR UTILITY IN LIGAND-RECEPTOR ASSAYS
United States of America	08/4583901	6/2/1995	5985579	11/16/1996	ANTIBODIES TO COMPLEXES OF LIGAND RECEPTORS AND LIGANDS AND THEIR UTILITY IN LIGAND-RECEPTOR ASSAYS
United States of America	08/101782	8/3/1993	5851776	12/22/1998	CONJUGATES AND ASSAYS FOR SIMULTANEOUS DETECTION OF MULTIPLE LIGANDS
United States of America	08/311098	9/23/1994	5763189	6/9/1998	FLUORESCENCE ENERGY TRANSFER AND INTRAMOLECULAR ENERGY TRANSFER IN MICROPARTICLES USING NOVEL COMPOUNDS
United States of America	08/409298	3/23/1995	6251687	6/26/2000	FLUORESCENCE ENERGY TRANSFER AND INTRAMOLECULAR ENERGY TRANSFER IN PARTICLES USING NOVEL COMPOUNDS
United States of America	08/3899669	2/15/1995	55610283	3/11/1997	OPIATE DERIVATIVES AND PROTEIN AND POLYPEPTIDE OPIATE DERIVATIVE CONJUGATION AND LABELS
United States of America	08/423582	4/18/1995	5795725	8/18/1998	NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	08/633248	4/18/1996	6174686	1/16/2001	NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS
United States of America	08/769077	12/18/1996	6827404	9/30/2003	METHODS FOR IMPROVING THE RECOVERY OF TROPONIN I AND T IN MEMBRANES, FILTERS AND VESSELS
United States of America	09/349194	7/7/1999	6939678	9/6/2005	NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS
United States of America	09/425318	10/21/1999	6579687	6/17/2003	NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS
United States of America	09/687051	10/12/2000	6991907	1/31/2006	NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS
United States of America	10/459006	6/10/2003			METHODS FOR IMPROVING THE RECOVERY OF TROPONIN I AND T IN MEMBRANES, FILTERS AND VESSELS
United States of America	10/850954	5/21/2004			NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS
United States of America	11/673397	2/9/2007			METHODS FOR IMPROVING THE RECOVERY OF TROPONIN I AND T IN MEMBRANES, FILTERS AND VESSELS
United States of America	08/517949	8/22/1995	6803040	10/12/2004	DERIVATIVES OF TRICYCLIC ANTIDEPRESSANTS AND PROTEIN AND POLYPEPTIDE TRICYCLIC ANTIDEPRESSANT DERIVATIVE CONJUGATES AND LABELS

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	08/704804	8/26/1996	6391265	5/21/2002	DEVICES INCORPORATING FILTERS FOR FILTERING FLUID SAMPLES
United States of America	10/153423	5/21/2002			DEVICES FOR INCORPORATING FILTERS FOR FILTERING FLUID SAMPLES
United States of America	08/620587	3/22/1996	5824799	10/20/1998	HYBRID PHTHALOCYANINE DERIVATIVES AND THEIR USES
United States of America	09/776589	2/1/2001	7083984	8/1/2006	HYBRID PHTHALOCYANINE DERIVATIVES AND THEIR USES
United States of America	08/274534	7/12/1994	6238931	5/29/2001	FLUORESCENCE ENERGY TRANSFER AND PARTICLES
United States of America	09/066255	4/24/1998	6364844	11/15/2005	HYBRID PHTHALOCYANINE DERIVATIVES AND THEIR USES
United States of America	11/448613	6/6/2006			HYBRID PHTHALOCYANINE DERIVATIVES AND THEIR USES
United States of America	08/749702	11/15/1996	6113855	9/5/2000	DEVICES COMPRISING MULTIPLE CAPILLARITY INDUCING SURFACES
United States of America	09/612815	7/10/2000	6669907	12/30/2003	DEVICES COMPRISING MULTIPLE CAPILLARITY INDUCING SURFACES
United States of America	10/746282	12/24/2003			DEVICES COMPRISING MULTIPLE CAPILLARITY INDUCING SURFACES
United States of America	08/837309	4/9/1997	6544797	4/8/2003	COMPOSITIONS AND METHODS FOR INHIBITING LIGHT-INDUCED INACTIVATION OF BIOLOGICAL REAGENTS
United States of America	10/338182	1/7/2003			NOVEL COMPOSITIONS AND METHODS FOR INHIBITING LIGHT-INDUCED INACTIVATION OF BIOLOGICAL REAGENTS
United States of America	09/081722	5/13/1998	6670196	12/30/2003	RAPID EVALUATION OF THE RATIO OF BIOLOGICAL MOLECULES
United States of America	10/697356	10/29/2003	7202042	4/10/2007	RAPID EVALUATION OF THE RATIO OF BIOLOGICAL MOLECULES
United States of America	08/821888	3/21/1997	5947124	9/7/1998	DIAGNOSTIC FOR DETERMINING THE TIME OF A HEART ATTACK
United States of America	08/942370	10/21/1997	6106779	8/22/2000	LYSIS CHAMBER FOR USE IN AN ASSAY DEVICE
United States of America	09/003066	15/1998	6074616	6/13/2000	MEDIA CARRIER FOR AN ASSAY DEVICE

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	09/545699	4/6/2000	6392894	5/21/2002	MEDIA CARRIER FOR AN ASSAY DEVICE
United States of America	07/299277	1/23/1989	5202234	4/13/1993	MYOCARDIAL INFARCTION ASSAY
United States of America	07/882299	5/13/1992	5326692	7/5/1994	FLUORESCENT MICROPARTICLES WITH CONTROLLABLE ENHANCED STOKES SHIFT
United States of America	09/358130	7/20/1999	6302919	10/16/2001	REVERSE-FLOW CENTRIFUGAL FILTRATION METHOD
United States of America	11/204764	8/15/2005			USE OF A GLUTATHIONE PEROXIDASE 1 AS A MARKER IN CARDIOVASCULAR CONDITIONS
United States of America	09/0036090	1/5/1998	6830731	12/14/2004	IMMUNOASSAY FLUOROMETER
United States of America	10/267232	10/8/2002			IMMUNOASSAY FLUOROMETER
United States of America	10/841274	5/7/2004			IMMUNOASSAY FLUOROMETER
United States of America	09/0036065	1/5/1998	6194222	2/27/2001	METHODS FOR MONITORING THE STATUS OF ASSAYS AND IMMUNOASSAYS
United States of America	09/712615	11/13/2000			METHODS FOR MONITORING THE STATUS OF ASSAYS AND IMMUNOASSAYS
United States of America	11/676032	2/16/2007			METHODS FOR MONITORING THE STATUS OF ASSAYS AND IMMUNOASSAYS
United States of America	08/993750	12/19/1997	6156521	12/5/2000	METHODS FOR THE RECOVERY AND MEASUREMENT OF TROPONIN COMPLEXES
United States of America	09/1835298	4/13/2001			USE OF B-TYPE NATRIURETIC PEPTIDE AS A PROGNOSTIC INDICATOR IN ACUTE CORONARY SYNDROMES
United States of America	10/389720	3/13/2003			USE OF B-TYPE NATRIURETIC PEPTIDE AS A PROGNOSTIC INDICATOR IN ACUTE CORONARY SYNDROMES
United States of America	10/225082	8/20/2002			DIAGNOSTIC MARKERS OF STROKE AND CEREBRAL INJURY AND METHOD OF USE THEREOF
United States of America	10/371149	2/20/2003			DIAGNOSTIC MARKERS OF STROKE AND CEREBRAL INJURY AND METHOD OF USE THEREOF

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	10/673077	9/26/2003			DIAGNOSTIC MARKERS OF STROKE AND CEREBRAL INJURY AND METHOD OF USE THEREOF
United States of America	10/714078	11/14/2003			DIAGNOSTIC MARKERS OF STROKE AND CEREBRAL INJURY AND METHODS OF USE THEREOF
United States of America	10/875800	6/23/2004			DIAGNOSTIC MARKERS OF STROKE AND CEREBRAL INJURY AND METHOD OF USE THEREOF
United States of America	10/330696	12/27/2002			MARKERS FOR DIFFERENTIAL DIAGNOSIS AND METHODS OF USE THEREOF
United States of America	10/728067	12/3/2003			USE OF THROMBUS PRECURSOR PROTEIN AND MONOCYTE CHEMOATTRACTANT PROTEIN AS DIAGNOSTIC AND PROGNOSTIC INDICATORS IN VASCULAR DISEASES
United States of America	10/952275	9/27/2004			METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF SEPSIS
United States of America	11/022552	12/23/2004			METHODS AND COMPOSITIONS FOR DETERMINING TREATMENT REGIMENS IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES
United States of America	10/759216	1/20/2004			BIMARKERS FOR SEPSIS
United States of America	11/543312	10/3/2006			METHODS AND COMPOSITIONS FOR DIAGNOSIS AND/OR PROGNOSIS IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES
United States of America	11/690767	3/23/2007			METHODS AND COMPOSITIONS FOR DIAGNOSIS AND/OR PROGNOSIS IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES
United States of America	11/770608	6/28/2007			METHODS AND COMPOSITIONS FOR DIAGNOSIS AND/OR PROGNOSIS IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES
United States of America					ARGININE ANALOGS AND METHODS FOR THEIR SYNTHESIS AND USE

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	10/1139086	5/4/2002			DIAGNOSTIC MARKERS OF ACUTE CORONARY SYNDROME AND METHODS OF USE THEREOF
United States of America	11/205571	8/17/2005			DIAGNOSTIC MARKERS OF ACUTE CORONARY SYNDROME AND METHODS OF USE THEREOF
United States of America	10/331127	12/27/2002			METHOD AND SYSTEM FOR DISEASE DETECTION USING MARKER COMBINATIONS
United States of America	10/410572	4/8/2003			SYSTEM AND METHOD FOR IDENTIFYING A PANEL OF INDICATORS
United States of America	10/603891	6/24/2003			(PROTEOME) MARKERS FOR DIFFERENTIAL DIAGNOSIS AND METHODS OF USE THEREOF
United States of America	11/7737621	4/19/2007			(PROTEOME) MARKERS FOR DIFFERENTIAL DIAGNOSIS AND METHODS OF USE THEREOF
United States of America	10/419059	4/17/2003			POLYPEPTIDES RELATED TO NATRIURETIC PEPTIDES AND METHODS OF THEIR IDENTIFICATION AND USE
United States of America	10/645874	8/20/2003			METHODS AND COMPOSITIONS FOR MEASURING BIOLOGICALLY ACTIVE NATRIURETIC PEPTIDES AND FOR IMPROVING THEIR THERAPEUTIC POTENTIAL
United States of America	10/938760	9/9/2004			METHODS AND COMPOSITIONS FOR MEASURING NATRIURETIC PEPTIDES AND USES THEREOF
United States of America	11/560425	11/16/2006			COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE AND MYOCARDIAL INFARCTION WITH DIPEPTIDYL PEPTIDASE INHIBITORS OR B-TYPE NATRIURETIC PEPTIDE ANALOGUES RESISTANT TO PROLYL-SPECIFIC DIPEPTIDYL DEGRADATION
United States of America	11/222494		9/7/2005		METHODS AND COMPOSITIONS FOR MEASURING CANINE BNP AND USES THEREOF

BIOSITE Case Listing

Country	Application Number	Application Date	Patent Number	Grant Date	Title
United States of America	10/7778919	2/12/2004	6887952	5/3/2005	N-ARYL-CARBAMIC ACID ESTER-DERIVED AND VALERIC ACID ESTER-DERIVED CROSS-LINKERS AND CONJUGATES AND METHODS FOR THEIR SYNTHESIS AND USE
United States of America	11/080211	3/14/2005	6967107	11/22/2005	N-ARYL-CARBAMIC ACID ESTER-DERIVED AND VALERIC ACID ESTER-DERIVED CROSS-LINKERS AND CONJUGATES AND METHODS FOR THEIR SYNTHESIS AND USE
United States of America	11/184746	7/19/2005			N-ARYL-CARBAMIC ACID ESTER-DERIVED AND VALERIC ACID ESTER-DERIVED CROSS-LINKERS AND CONJUGATES AND METHODS FOR THEIR SYNTHESIS AND USE
United States of America	11/450150		6/9/2006		METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF VENOUS THROMBOEMBOLIC DISEASE

**SCHEDULE 1C
TO
FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT**

See attached list of trademarks

COUNTRY	TRADEMARK	CLASS(ES)	APPL. NO. FILING DATE	REG. NO. ISSUE DATE
US	AN UNFAIR ADVANTAGE	1, 42	75/609619 12/21/1998	2453707 05/22/2001
US	BIOSITE DISCOVERY AN UNFAIR ADVANTAGE & Design	1, 5, 42	75/655110 03/05/1999	2456330 05/29/2001
US	OMNICLONAL	1, 5	75/609841 12/21/1998	2476239 08/07/2001

MARK	COUNTRY	SERIAL NO. FILING DATE	REG. NO./ REG. DATE
MULTI MARKER INDEX	USA	78/574,678 02/24/2005	

TRADEMARK
REEL: 003575 FRAME: 0276

Biosite (U.S. only)

Docket Number	Country	Mark		Portfolio Status	Owner No	Application Date	Registration Date	Registration Number
071949-4501	United States of America	IN TIME TO DECIDE		Registered	Biosite Inc	78/056518	4/3/2001	7/30/2002 2601205
071949-4601	United States of America	NEW DIMENSIONS IN DIAGNOSIS		Registered	Biosite Inc	78/072981	7/9/2001	8/26/2003 2757467
071949-4701	United States of America	ASCEND MULTIMUNOASSAY		Registered	Biosite Inc	74/489582	2/14/1994	10/3/1995 1923243
071949-4801	United States of America	BIOSITE (Stylized)		Registered	Biosite Inc	74/260208	3/30/1992	9/28/1993 1794618
071949-4802	United States of America	BIOSITE (Stylized)		Registered	Biosite Inc	74/260475	3/30/1992	10/5/1993 1796567
071949-4819	United States of America	BIOSITE and Design		Registered	Biosite Inc	76/634473	3/28/2005	10/10/2006 3152581
071949-5101	United States of America	TRIAGE		Registered	Biosite Inc	74/525008	5/16/1994	2/6/1996 1954150
071949-5202	United States of America	TpP Stylized		Registered	Biosite Inc	75/172105	9/26/1996	1/14/2003 2673476
071949-6401	United States of America	EXPRESS TEST		Registered	Biosite Inc	75/075619	3/20/1996	12/1/1998 2207727
071949-6402	United States of America	EXPRESS TEST and Design		Registered	Biosite Inc	75/099733	5/2/1996	9/21/1999 2279640
071949-8101	United States of America	CARDIO PROFILER		Registered	Biosite Inc	78/178159	10/24/2002	6/7/2005 2960760

RECORDED: 07/05/2007

TRADEMARK
REEL: 003575 FRAME: 0277